{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:12:17Z","timestamp":1784311937996,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroscience Methods"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jneumeth.2025.110415","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T16:06:58Z","timestamp":1741450018000},"page":"110415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis"],"prefix":"10.1016","volume":"418","author":[{"given":"Anshul","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-748X","authenticated-orcid":false,"given":"Nitin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushagra","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshita","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Mehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jneumeth.2025.110415_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jneumeth.2025.110415_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jneumeth.2025.110415_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"7","key":"10.1016\/j.jneumeth.2025.110415_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","article-title":"Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?","volume":"3","author":"Gajofatto","year":"2015","journal-title":"World J. Clin. Cases: WJCC"},{"key":"10.1016\/j.jneumeth.2025.110415_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chemphyslip.2017.06.002","article-title":"Effect of physical exercise on brain and lipid metabolism in mouse models of multiple sclerosis","volume":"207","author":"Houdebine","year":"2017","journal-title":"Chem. Phys. Lipids"},{"issue":"1","key":"10.1016\/j.jneumeth.2025.110415_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2014.08.003","article-title":"In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery","volume":"474","author":"Jose","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jneumeth.2025.110415_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2022.105177","article-title":"Nose-to-brain lipid nanocarriers: an active transportation across BBB in migraine management","volume":"243","author":"Kataria","year":"2022","journal-title":"Chem. Phys. Lipids"},{"issue":"6","key":"10.1016\/j.jneumeth.2025.110415_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.nano.2010.06.003","article-title":"Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax","volume":"6","author":"Kheradmandnia","year":"2010","journal-title":"Nanomed. Nanotechnol., Biol. Med."},{"issue":"7","key":"10.1016\/j.jneumeth.2025.110415_bib9","first-page":"492","article-title":"Enhancement in brain uptake of vitamin D(3) nanoemulsion for treatment of cerebral ischemia: formulation, gamma scintigraphy and efficacy study in transient middle cerebral artery occlusion rat models","volume":"37","author":"Kumar","year":"2020","journal-title":"J. Micro."},{"key":"10.1016\/j.jneumeth.2025.110415_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11011-021-00691-x","article-title":"Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain","volume":"36","author":"Kumar","year":"2021","journal-title":"Metab. brain Dis."},{"key":"10.1016\/j.jneumeth.2025.110415_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/584549","article-title":"Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability","volume":"2013","author":"Kushwaha","year":"2013","journal-title":"BioMed Res. Int."},{"issue":"2","key":"10.1016\/j.jneumeth.2025.110415_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.jneumeth.2025.110415_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneumeth.2025.110415_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2015.09.014","article-title":"Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach","volume":"495","author":"Makwana","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jneumeth.2025.110415_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14656566.2015.1002769","article-title":"Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs","volume":"16","author":"Milo","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.jneumeth.2025.110415_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101640","article-title":"Nose to brain delivery of phenytoin sodium loaded nano lipid carriers: formulation, drug release, permeation and in vivo pharmacokinetic studies","volume":"13","author":"Nair","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jneumeth.2025.110415_bib17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/10837450.2015.1108982","article-title":"Nanoparticulate fingolimod delivery system based on biodegradable poly (3-hydroxybutyrate-co-3-hydroxyvalerate)(PHBV): design, optimization, characterization and in-vitro evaluation","volume":"22","author":"Rezaie Shirmard","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jneumeth.2025.110415_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol. Sci."},{"issue":"S1 1","key":"10.1016\/j.jneumeth.2025.110415_bib19","first-page":"S123","article-title":"Symptom management in multiple sclerosis","volume":"36","author":"Schapiro","year":"1994","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"10.1016\/j.jneumeth.2025.110415_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.toxrep.2019.10.019","article-title":"Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: insights from behavioral and biochemical evidence","volume":"6","author":"Sharma","year":"2019","journal-title":"Toxicol. Rep."},{"issue":"8","key":"10.1016\/j.jneumeth.2025.110415_bib21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1742-1241.2011.02721.x","article-title":"Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis","volume":"65","author":"Singer","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.jneumeth.2025.110415_bib22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/np2000528","article-title":"Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite","volume":"74","author":"Strader","year":"2011","journal-title":"J. Nat. Prod."},{"issue":"14","key":"10.1016\/j.jneumeth.2025.110415_bib23","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.jneumeth.2025.110415_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12668-022-00972-4","article-title":"Intranasal administration of microvesicles in the brain of mice with induced model of Alzheimer\u2019s type of neurodegeneration","volume":"12","author":"Zhdanova","year":"2022","journal-title":"BioNanoScience"},{"issue":"2","key":"10.1016\/j.jneumeth.2025.110415_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/02652048.2022.2051626","article-title":"The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review","volume":"39","author":"Zuglianello","year":"2022","journal-title":"J. Microencapsul."}],"container-title":["Journal of Neuroscience Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165027025000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165027025000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:13:21Z","timestamp":1778040801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165027025000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"alternative-id":["S0165027025000561"],"URL":"https:\/\/doi.org\/10.1016\/j.jneumeth.2025.110415","relation":{},"ISSN":["0165-0270"],"issn-type":[{"value":"0165-0270","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroscience Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneumeth.2025.110415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110415"}}